Navigation Links
Synosia Starts Phase II Efficacy Trial For Rufinamide
Date:3/31/2008

The drug was originally discovered and developed by Novartis, which in 2004 granted certain licensing rights to Eisai, excluding anxiety and mood disorders. In January 2007, Eisai received marketing authorisation in the European Union for Inovelon(R) (rufinamide) as adjunctive anti-epileptic therapy in Lennox-Gastaut Syndrome (LGS), a severe form of epilepsy that develops in early childhood. The extensive clinical development program for rufinamide in epilepsy has generated over 2500 patient years of exposure to the drug.

About Synosia Therapeutics

Synosia Therapeutics develops and intends to commercialize innovative and clinically differentiated products for unmet medical needs in psychiatry and neurology. The privately-owned company has six clinical-stage compounds in its pipeline, acquired through key partnerships with Novartis, Roche and Syngenta. Synosia's pipeline includes two marketed drugs that will be tested in new indications, extending their reach into neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's Disease. Synosia's headquarters is in Basel, Switzerland. For more information visit http://www.synosia.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Synosia Therapeutics and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Synosia Therapeutics to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Synosia Therapeutics is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

References

'/>"/>
SOURCE Synosia Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Synosia Therapeutics Announces Appointment of Chief Business Officer
2. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
3. Synosia Therapeutics Appoints Chief Financial Officer to New Company Headquarters in Switzerland
4. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
5. Evotec Starts Phase II in Smoking Cessation with EVT 302
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
11. Phase III Trial Finds Pharmaxis Bronchitol Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... new study by researchers from the University of ... nanosystems function, unlocking the potential to create new ... which has been published in the prestigious academic ... novel laser technique to examine in rich detail ... small cluster containing an acetylene molecule and a ...
(Date:7/25/2014)... WABC Radio show out of New York City, ... will be hosting California-based Vet-Stem, Inc.’s Founder and CEO, Robert ... pets. Dr. Harman first visited the show in November ... pets suffering from osteoarthritis and other degenerative diseases, as well ... , Young has invited Dr. Harman back to dial down ...
(Date:7/25/2014)... July 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... on the development and commercialization of a once-daily, oral ... gallstones, today announced financial results for the period ended ... Summary: , Reported cash and cash equivalents totaling ... at December 31, 2013.  , Reported a net ...
(Date:7/25/2014)... , July 25, 2014 Sinovac Biotech Ltd. ... products in China , today announced that ... quarter ended June 30, 2014, after market close on Thursday, ... call prior to the market opening on Friday, August 15, ... 8:00 p.m. China Standard Time) to review the Company,s financial ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2
... , CARLSBAD, Calif. ; May 24 ... water and microbial nucleic acid purification, announces the launch ... Bead-Based Homogenizer, for powerful, fast and reliable homogenization and ... will enable researchers to prepare samples for analysis faster, ...
... ... flagship research institute, is holding its first ever International Rational Genome Design Contest (GenoCon) ... science research known as the RIKEN Scientists’ Networking System (SciNeS*2) and will take place ... ...
... May 24 Dynamic, thorough, and robustly qualified ... newest Scientific Content Consultant, Philippe Vitat, who brings with him ... Vitat has worked as a certified medical writer and editor ... the World" in medical education by the International Biographical Center ...
Cached Biology Technology:MO BIO Laboratories, Inc. Launches PowerLyzer(TM) 24 Bench Top Bead-Based Homogenizer 2Launch of GenoCon: First-ever Contest in Rational Genome Design Based on Semantic-web Technology 2Launch of GenoCon: First-ever Contest in Rational Genome Design Based on Semantic-web Technology 3Launch of GenoCon: First-ever Contest in Rational Genome Design Based on Semantic-web Technology 4Launch of GenoCon: First-ever Contest in Rational Genome Design Based on Semantic-web Technology 5Highly Regarded Medical Writer Joins Avant Healthcare Marketing Team 2
(Date:7/28/2014)... led by the University of Arizona has sequenced the ... will enhance scientists, and agriculturalists, understanding of the growing ... development of new rice varieties that are better able ... global hunger challenges. , The paper, "The genome sequence ... for independent domestication," was published online in Nature ...
(Date:7/28/2014)... juvenile rat brain cells suggests that the effects of ... brain cells are temporary. , The study, published in ... , was conducted by biologists at the University of ... New York in response to concerns, arising from multiple ... children to general anesthetics may increase their susceptibility to ...
(Date:7/28/2014)... identified areas of the Earth that are high priorities ... Europe is particularly vulnerable, as it has the lowest ... of any continent in ,refugia, areas of biological ... remain relatively constant during times of great environmental change. ... in Scandinavia and Scotland. , The biggest refugia ...
Breaking Biology News(10 mins):Generating a genome to feed the world: UA-led team sequences African rice 2Generating a genome to feed the world: UA-led team sequences African rice 3Generating a genome to feed the world: UA-led team sequences African rice 4Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3Study finds Europe's habitat and wildlife is vulnerable to climate change 2
... could lead to new asthma drugs, scientists at Yale School ... of California, San Francisco have discovered that a protein may ... demonstrated how a drug known to reduce inflammatory and neuropathic ... is published in the May 18-22 online Early Edition of ...
... project that aims to produce hydrogen on an environmentally ... sun has won a prestigious E.ON research award. ... abundant and renewable sources sunlight, biomass and water. ... degradation of organic compounds avoiding the use of energy ...
... cases of malaria are diagnosed each year mostly in ... malaria do exist, the demand for new treatments is ... developed a resistance to existing medications. Now, researchers ... discovered one way to stop malaria parasite growth, and ...
Cached Biology News:Yale team identifies key to potential new treatment for allergy-induced asthma 2Accolade for solar-hydrogen project 2New lead on malaria treatment 2
... Blue LED produces output at 470 nm; ... with an S2000 or installed into rack or ... Pulsed Light Source is an LED that produces ... -- the blue region -- for fluorescence measurements. ...
... amber to slightly cloudy liquid. Yellow, ... per set, each containing 10 ml ... the following proportions by weight: 85% ... monooleate emulsifier), and 0.1% Mycobacterium ...
For removal of the zona pellucida. Sterile, Mouse Embryo tested...
Imject Freund's Complete Adjuvant (FCA)...
Biology Products: